Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer (Q35968742)

11 August 2017

1 reference

title

Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer (English)

1 reference

11 August 2017

1 reference

1 reference

Robert F Ozols

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

22 Suppl 2

1 reference

11 August 2017

page(s)

11-20

1 reference

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

21 January 2018

Maybe more is better.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-200030113

21 January 2018

Identifiers

DOI

10.1081/CNV-200030113

1 reference

11 August 2017

1 reference